| Bioactivity | CX546 is a first-generation and selective benzamide-type positive AMPAR modulator. CX546 is a prototypical ampakine agent and has antipsychotic effects[1][2]. | ||||||||||||
| In Vivo | Treatment with the ampakine CX614 (intraperitoneal injection) markedly and reversibly increase brain-derived neurotrophic factor (BDNF) mRNA and protein levels in cultured rat entorhinal/hippocampal slices[1]. | ||||||||||||
| Name | CX546 | ||||||||||||
| CAS | 215923-54-9 | ||||||||||||
| Formula | C14H17NO3 | ||||||||||||
| Molar Mass | 247.29 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Lauterborn JC, et al. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci. 2000 Jan 1;20(1):8-21. [2]. Lipina T, et al. The ampakine CX546 restores the prepulse inhibition and latent inhibition deficits in mGluR5-deficient mice. Neuropsychopharmacology. 2007 Apr;32(4):745-56. |